Robert Harrington to Coronary Angiography
This is a "connection" page, showing publications Robert Harrington has written about Coronary Angiography.
Connection Strength
1.758
-
Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. Int J Cardiol. 2016 Jan 15; 203:708-13.
Score: 0.087
-
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention. 2015 Nov; 11(7):737-45.
Score: 0.086
-
Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy. Am Heart J. 2015 Aug; 170(2):371-9.
Score: 0.084
-
Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. J Thromb Thrombolysis. 2013 Nov; 36(4):384-93.
Score: 0.075
-
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv. 2013 Jul; 6(7):671-83.
Score: 0.074
-
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. Eur Heart J Acute Cardiovasc Care. 2014 Mar; 3(1):37-45.
Score: 0.073
-
Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. JACC Cardiovasc Interv. 2012 Sep; 5(9):927-35.
Score: 0.069
-
Metabolic syndrome is not associated with increased mortality or cardiovascular risk in nondiabetic patients with a new diagnosis of coronary artery disease. Circ Cardiovasc Qual Outcomes. 2010 Mar; 3(2):165-72.
Score: 0.058
-
Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. Am Heart J. 2009 Apr; 157(4):716-23.
Score: 0.055
-
Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 May 21; 360(21):2176-90.
Score: 0.055
-
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV). Am J Cardiol. 2008 Sep 01; 102(5):546-51.
Score: 0.052
-
Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters. Ann Thorac Surg. 2008 Feb; 85(2):520-4.
Score: 0.051
-
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 2007 Dec 04; 116(23):2669-77.
Score: 0.050
-
Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007 Nov 15; 100(10):1538-42.
Score: 0.049
-
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. Am Heart J. 2006 Feb; 151(2):316-22.
Score: 0.044
-
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):513S-548S.
Score: 0.040
-
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6.
Score: 0.039
-
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. Am J Med. 2004 Jan 15; 116(2):119-29.
Score: 0.038
-
Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial. Eur Heart J Acute Cardiovasc Care. 2022 Jun 07; 11(4):336-349.
Score: 0.034
-
Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial. Circ Cardiovasc Interv. 2022 04; 15(4):e010925.
Score: 0.034
-
Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020 04 09; 382(15):1395-1407.
Score: 0.029
-
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019 Sep 28; 394(10204):1169-1180.
Score: 0.028
-
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10?854 patients from the CHAMPION PHOENIX trial. Eur Heart J. 2018 12 07; 39(46):4112-4121.
Score: 0.027
-
Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2018 05 14; 11(9):856-864.
Score: 0.026
-
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2018 02; 196:28-35.
Score: 0.025
-
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. Am Heart J. 2017 Jun; 188:147-155.
Score: 0.024
-
The Systematic Evaluation of Identifying the Infarct Related Artery Utilizing Cardiac Magnetic Resonance in Patients Presenting with ST-Elevation Myocardial Infarction. PLoS One. 2017; 12(1):e0169108.
Score: 0.023
-
Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. Int J Cardiol. 2017 Apr 01; 232:264-270.
Score: 0.023
-
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem. 2017 Feb; 63(2):573-584.
Score: 0.023
-
Radial access in patients with acute coronary syndrome without persistent ST-segment elevation: Systematic review, collaborative meta-analysis, and meta-regression. Int J Cardiol. 2016 Nov 01; 222:1031-1039.
Score: 0.023
-
Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. Circulation. 2016 Jan 12; 133(2):131-8.
Score: 0.022
-
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. Circ Cardiovasc Qual Outcomes. 2015 Jul; 8(4):357-67.
Score: 0.021
-
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. J Am Coll Cardiol. 2013 Apr 02; 61(13):1461-3.
Score: 0.018
-
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012 May; 163(5):768-776.e2.
Score: 0.017
-
Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circ Cardiovasc Qual Outcomes. 2012 Mar 01; 5(2):205-13.
Score: 0.017
-
Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012 Feb; 163(2):182-90.e4.
Score: 0.017
-
Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. Circulation. 2012 Feb 14; 125(6):749-56.
Score: 0.017
-
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation. 2011 Feb 22; 123(7):722-30.
Score: 0.016
-
Sex differences in mortality following acute coronary syndromes. JAMA. 2009 Aug 26; 302(8):874-82.
Score: 0.014
-
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med. 2009 Jul 16; 361(3):235-44.
Score: 0.014
-
Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2008 Nov; 136(5):1149-55.
Score: 0.013
-
Noninvasive, medical management for non-ST-elevation acute coronary syndromes. Am Heart J. 2008 Mar; 155(3):397-407.
Score: 0.013
-
Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV. Ann Thorac Surg. 2008 Feb; 85(2):494-9; discussion 499-500.
Score: 0.013
-
ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation. 2007 Jan 23; 115(3):402-26.
Score: 0.012
-
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheter Cardiovasc Interv. 2007 Jan; 69(1):73-83.
Score: 0.012
-
Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. Am J Cardiol. 2005 Nov 01; 96(9):1254-9.
Score: 0.011
-
Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol. 2005 Feb 01; 95(3):383-6.
Score: 0.010
-
Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jan 18; 45(2):321-3.
Score: 0.010
-
Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease. Am J Cardiol. 2005 Jan 15; 95(2):182-8.
Score: 0.010
-
Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation. 2004 Aug 10; 110(6):679-84.
Score: 0.010
-
Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol. 2004 Jun 01; 93(11):1362-7, A5-6.
Score: 0.010
-
Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Can J Cardiol. 2004 Jun; 20(8):773-8.
Score: 0.010
-
Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. Am Heart J. 2004 May; 147(5):847-52.
Score: 0.010
-
Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Feb 18; 43(4):549-56.
Score: 0.010
-
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. Am J Med. 2003 Dec 01; 115(8):613-9.
Score: 0.009
-
Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). Am J Cardiol. 2003 Sep 15; 92(6):660-4.
Score: 0.009
-
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol. 2003 Apr 16; 41(8):1251-60.
Score: 0.009
-
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy). Cardiology. 2002; 98(4):195-201.
Score: 0.008